The estimated Net Worth of John B Ziegler is at least $3.63 million dollars as of 22 February 2017. John Ziegler owns over 2,000 units of Quest Diagnostics stock worth over $2,542,493 and over the last 21 years John sold DGX stock worth over $1,091,577.
John has made over 17 trades of the Quest Diagnostics stock since 2011, according to the Form 4 filled with the SEC. Most recently John sold 2,000 units of DGX stock worth $191,020 on 22 February 2017.
The largest trade John's ever made was exercising 31,362 units of Quest Diagnostics stock on 21 May 2013 worth over $1,401,881. On average, John trades about 2,560 units every 45 days since 2003. As of 22 February 2017 John still owns at least 16,557 units of Quest Diagnostics stock.
You can see the complete history of John Ziegler stock trades at the bottom of the page.
John's mailing address filed with the SEC is , , , , .
Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty et Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
Quest Diagnostics executives and other stock owners filed with the SEC include: